Volume 2.04 | Feb 5

Immune Regulation News 2.04, February 5, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


New Understanding of CD44 Receptor’s Role in Immune Cell Survival
Investigators have discovered a new way the cell surface protein, CD44, helps specific T helper 1 cells develop immunologic memory. [Press release from EurekAlert discussing online prepublication in Immunity]

Request A Poster  
Isolate Untouched Cells for
Antigen Processing and Presentation
with EasySep®


Video – EasySep®Pour-off – A Simple and Effective Way to Isolate Cells


Preventing Pancreatic Islet Loss after Transplantation
By studying islet transplantation in a mouse model of diabetes, researchers have now identified a potential new set of targets to improve the efficiency of pancreatic islet transplantation. [Press release from EurekAlert discussing online prepublication in The Journal of Clinical Investigation]



Signaling by Intrathymic Cytokines, not T Cell Antigen Receptors, Specifies CD8 Lineage Choice and Promotes the Differentiation of Cytotoxic-Lineage T Cells
Cytokine signaling is required for positively selected thymocytes to express the transcription factor Runx3, specify CD8 lineage choice and differentiate into cytotoxic-lineage T cells. [Nat Immunol]

High-Mobility Group Box 1 is Involved in the Initial Events of Early Loss of Transplanted Islets in Mice
Findings indicate that the high-mobility group box 1-mediated pathway eliciting early islet loss is a potential target for intervention to improve the efficiency of islet transplantation. [J Clin Invest]

Inhibitory Role for GABA in Autoimmune Inflammation
Researchers demonstrate that immune cells synthesize GABA, the principal inhibitory neurotransmitter in the adult brain, and have the machinery for GABA catabolism. [Proc Natl Acad Sci]

Activation State and Intracellular Trafficking Contribute to the Repertoire of Endogenous Glycosphinogolipids Presented by CD1d
This report identifies the range of glycosphingolipids bound to soluble murine CD1d (mCD1d) molecules that sample the endoplasmic reticulum/secretory routes and cell surface-cleaved mCD1d that also samples the endocytic system. [Proc Natl Acad Sci]

Regulation of Autoreactive B Cell Responses to Endogenous Toll-Like Receptor Ligands
Evidence suggests that B cell activation by BCR/toll-like receptor pathways is tightly regulated by surface-expressed receptors on B cells, and the outcome of activation depends on the balance of stimulatory and inhibitory signals. [J Autoimmun]

Regulatory T Cells Attenuate Th17 Cell-Mediated Nigrostriatal Dopaminergic Neurodegeneration in a Model of Parkinson’s Disease
These results demonstrate regulatory T cell control of N-alpha-syn-induced neurodestructive immunity and, as such, provide a sound rationale for future Parkinson’s disease immunization strategies. [J Immunol]

IL-17 Promotes Tumor Development through the Induction of Tumor Promoting Microenvironments at Tumor Sites and Myeloid-Derived Suppressor Cells
The IL-17R deficiency increased CD8 T cell infiltration, whereas it reduced the infiltration of myeloid-derived suppressor cells (MDSCs) in tumors. In contrast, administration of IL-17 inhibited CD8 T cell infiltration and increased MDSCs in tumors. [J Immunol]

T Cell Polarization Depends on Concentration of the Danger Signal Used to Activate Dendritic Cells
This study reveals that bone marrow-derived dendritic cells (BMDCs) pulsed with LPS-free ovalbumine did not induce allergic disease. However, when BMDCs were activated with low-dose LPS during pulsing with allergen, these cells expressed an inflammatory set of cytokines and co-stimulatory molecules like CD86 and OX40L. [Immunol Cell Biol]



Compugen Shares Soar Premarket As Company Discovers New Protein
Shares of Compugen Ltd. soared premarket as the Israeli drug-discovery company said it has discovered a new protein for the treatment of autoimmune disorders. [The Wall Street Journal]

XOMA Announces $21 Million Underwritten Offering of Common Shares and Warrants
XOMA Ltd. announced the pricing of an underwritten offering of 42 million units at a price to investors of $0.50 per unit for gross proceeds of approximately $21.0 million. [CNN Money]


Notice of Availability of Administrative Supplements for R25 Science Education Grants (NOT-DA-10-007)  [National Institutes of Health, United States]

Recovery Act Limited Competition: Program to Enhance NIH-supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001)
[National Institutes of Health, United States]

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096)
[National Heart, Lung, and Blood Institute, United States]

NIDDK Centers of Excellence in Molecular Hematology (P30) (RFA-DK-09-013) [National Institute of Diabetes and Digestive and Kidney Diseases, United States]

Public consultation (MLX 366): Intention to amend the Medicines for Human Use (Prescribing by EEA Practitioners) Regulations 2008 (SI 2008/1692) [The Medicines and Healthcare products Regulatory Agency, United Kingdom]


13th International Conference on Lymphocyte Activation and Immune Regulation: Inflammasome and Inflammation
February 5-7, 2010
Newport Beach, United States

Keystone Symposia: Tolerance and Autoimmunity
February 21-26, 2010
Taos, United States

World Immune Regulation Meeting (WIRM) – IV
March 29-April 1, 2010
Davos, Switzerland

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

May 7-11, 2010
Baltimore, United States

14th International Congress of Immunology
August 22-27, 2010
Kobe, Japan

Visit our events page  to stay up to date with the latest events in the cell, gene and immunotherapy community.


Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Immune Regulation News? Click here to submit!


Learn more about Immune Regulation News: Archives  |  Events  |  Subscribe  |  Contact Us